Joaquin Arribas

List of Publications by Year
in descending order

126 papers	10,453 citations	38660 50 h-index	33814 99 g-index
135 all docs	135 docs citations	135 times ranked	16195 citing authors

#	Article	IF	Citations
1	IFNÎ³ Signaling in Natural and Therapy-Induced Antitumor Responses. Clinical Cancer Research, 2022, 28, 1243-1249.	3.2	15
2	LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer, 2022, 3, 355-370.	5.7	21
3	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.4	40
4	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Research Communications, 2022, 2, 110-130.	0.7	10
5	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science Advances, 2022, 8, .	4.7	21
6	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers, 2022, 14, 2562.	1.7	6
7	Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. Journal of Steroid Biochemistry and Molecular Biology, 2021, 208, 105735.	1.2	9
8	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nature Communications, 2021, 12, 1237.	5.8	29
9	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British Journal of Cancer, 2021, 124, 1581-1591.	2.9	12
10	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Research, 2021, 23, 42.	2.2	11
11	The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAFâ€“MEK1/2â€“ERK1/2 Pathway. Cancer Research, 2021, 81, 3849-3861.	0.4	14
12	DNA hypomethylating agents increase activation and cytolytic activity of CD8+ TÂcells. Molecular Cell, 2021, 81, 1469-1483.e8.	4.5	52
13	Overview of virus and cancer relationships. Position paper. Revista Espanola De Quimioterapia, 2021, 34, 525-555.	0.5	2
14	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5096-5108.	3.2	12
15	E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. Oncogene, 2021, 40, 6614-6626.	2.6	7
16	HER2â€‰+â€‰breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	5.8	47
17	LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. Oncogene, 2020, 39, 79-121.	2.6	28
18	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	3.6	10

#	Article	IF	Citations
19	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2020, 19, 1289-1297.	1.9	11
20	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers, 2020, 12, 670.	1.7	31
21	Enhancing global access to cancer medicines. Ca-A Cancer Journal for Clinicians, 2020, 70, 105-124.	157.7	123
22	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer, 2020, 20, 99.	1.1	31
23	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	3.2	21
24	Chromosome 12p Amplification in Triple-Negative/<i>BRCA1-</i>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
25	MEN1309/OBT076, a First-In-Class Antibodyâ€"Drug Conjugate Targeting CD205 in Solid Tumors. Molecular Cancer Therapeutics, 2019, 18, 1533-1543.	1.9	18
26	HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503. Scientific Reports, 2019, 9, 3352.	1.6	15
27	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. Cancer Letters, 2019, 453, 34-44.	3.2	12
28	Therapeutic targeting of HER2â€"CB ₂ R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	3.3	40
29	Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist, 2019, 24, 680-687.	1.9	7
30	Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. Clinical Cancer Research, 2019, 25, 2588-2600.	3.2	11
31	TGFÎ²-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. Cancer Research, 2019, 79, 33-46.	0.4	70
32	Coamplification of <i>miR-4728</i> protects <i>HER2</i> -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2594-E2603.	3.3	23
33	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	0.6	280
34	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology, 2018, 20, 211-221.	4.6	98
35	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	0.8	43
36	p95HER2â€"T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	5.8	59

#	Article	IF	Citations
37	PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells. Cancer Cell, 2018, 34, 85-102.e9.	7.7	152
38	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 6367-6382.	3.2	52
39	Silencing of adaptor protein <scp>SH</scp>3<scp>BP</scp>2 reduces <scp>KIT</scp>/<scp>PDGFRA</scp> receptors expression and impairs gastrointestinal stromal tumors growth. Molecular Oncology, 2018, 12, 1383-1397.	2.1	12
40	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	12.8	527
41	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clinical Cancer Research, 2017, 23, 7006-7019.	3.2	61
42	Resistance to the Antibodyâ€“Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Research, 2017, 77, 4639-4651.	0.4	103
43	Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. Oncotarget, 2017, 8, 93688-93703.	0.8	7
44	Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene, 2017, 36, 5639-5647.	2.6	19
45	Cancer network activity associated with therapeutic response and synergism. Genome Medicine, 2016, 8, 88.	3.6	7
46	Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ). Annals of Oncology, 2016, 27, vi213.	0.6	0
47	High HER2 protein levels correlate with increased survival in breast cancer patients treated with antiâ€HER2 therapy. Molecular Oncology, 2016, 10, 138-147.	2.1	76
48	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 2016, 7, 56295-56308.	0.8	83
49	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, 7, 67956-67965.	0.8	4
50	Targeting the EGF/HER Ligand-Receptor System in Cancer. Current Pharmaceutical Design, 2016, 22, 5887-5898.	0.9	51
51	Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Research, 2015, 17, 106.	2.2	10
52	Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers. Journal of the National Cancer Institute, 2015, 107, djv020-djv020.	3.0	32
53	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	3.2	71
54	Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma. Cancer Research, 2015, 75, 1675-1681.	0.4	95

#	Article	IF	Citations
55	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE, 2015, 10, e0129876.	1.1	45
56	Abstract 396: Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma. , 2015, , .		0
57	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
58	Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. Journal of Proteome Research, 2014, 13, 3706-3721.	1.8	7
59	Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer, 2014, 50, 2725-2734.	1.3	25
60	PELO negatively regulates HER receptor signalling and metastasis. Oncogene, 2014, 33, 1190-1197.	2.6	13
61	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2014, 124, 1418-1418.	3.9	0
62	A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene, 2013, 32, 1452-1459.	2.6	9
63	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. Cancer Research, 2013, 73, 450-458.	0.4	76
64	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i>V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	7.7	43
65	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2013, 123, 2551-2563.	3.9	108
66	Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.. , 2013, , .		0
67	The protease MT1â€MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB Journal, 2012, 26, 4481-4494.	0.2	34
68	SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis. Nature Neuroscience, 2011, 14, 562-569.	7.1	86
69	ADAM17 (TACE) regulates TGFÎ² signaling through the cleavage of vasorin. Oncogene, 2011, 30, 1912-1922.	2.6	75
70	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	2.6	471
71	p95HER2 and Breast Cancer. Cancer Research, 2011, 71, 1515-1519.	0.4	195
72	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research, 2010, 70, 8537-8546.	0.4	47

#	Article	IF	Citations
73	Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene, 2010, 29, 325-334.	2.6	106
74	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2â€“Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	3.2	137
75	HER2 Fragmentation and Breast Cancer Stratification. Clinical Cancer Research, 2010, 16, 4071-4073.	3.2	13
76	The Cleavage of Semaphorin 3C Induced by ADAMTS1 Promotes Cell Migration. Journal of Biological Chemistry, 2010, 285, 2463-2473.	1.6	92
77	Abstract 850: 32H2, a new diagnostic tool for HER2 CTFs. , 2010, , .		0
78	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331.	1.1	150
79	HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation. Journal of Biological Chemistry, 2009, 284, 25302-25313.	1.6	28
80	ADAM17 as a Therapeutic Target in Multiple Diseases. Current Pharmaceutical Design, 2009, 15, 2319-2335.	0.9	149
81	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 2009, 28, 803-814.	2.6	385
82	Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. British Journal of Cancer, 2008, 99, 1607-1612.	2.9	79
83	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research, 2008, 68, 8022-8030.	0.4	726
84	Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biological Chemistry, 2008, 389, 1075-1084.	1.2	32
85	Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. Biological Chemistry, 2008, .	1.2	0
86	Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors. Journal of Biological Chemistry, 2007, 282, 8325-8331.	1.6	60
87	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 628-638.	3.0	769
88	Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO Journal, 2006, 25, 3234-3244.	3.5	196
89	ADAMs, cell migration and cancer. Cancer and Metastasis Reviews, 2006, 25, 57-68.	2.7	113
90	Proteomic Identification of Desmoglein 2 and Activated Leukocyte Cell Adhesion Molecule as Substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis. Molecular and Cellular Biology, 2006, 26, 5086-5095.	1.1	106

#	Article	IF	Citations
91	N-terminal cleavage of proTGFÎ± occurs at the cell surface by a TACE-independent activity. Biochemical Journal, 2005, 389, 161-172.	1.7	19
92	Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. British Journal of Cancer, 2005, 93, 1267-1276.	2.9	95
93	ADAM 17. , 2005, , 171-197.		3
94	Matrix Metalloproteases and Tumor Invasion. New England Journal of Medicine, 2005, 352, 2020-2021.	13.9	18
95	Recycling of Cell Surface Pro-transforming Growth Factor-Î± Regulates Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry, 2005, 280, 36970-36977.	1.6	7
96	Who will benefit from treatment against EGFR?. Lancet Oncology, The, 2005, 6, 257-258.	5.1	13
97	The Shedding of Betaglycan Is Regulated by Pervanadate and Mediated by Membrane Type Matrix Metalloprotease-1. Journal of Biological Chemistry, 2004, 279, 7721-7733.	1.6	119
98	Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225). Clinical Cancer Research, 2004, 10, 6487-6501.	3.2	273
99	Treating cancer's kinase 'addiction'. Nature Medicine, 2004, 10, 786-787.	15.2	56
100	Inactivating mutations block the tumor necrosis factor-Î±-converting enzyme in the early secretory pathway. Biochemical and Biophysical Research Communications, 2004, 314, 1028-1035.	1.0	21
101	Impaired trafficking and activation of tumor necrosis factor-Î±-converting enzyme in cell mutants defective in protein ectodomain shedding. Vol. 278 (2003) 25933â€“25939. Journal of Biological Chemistry, 2004, 279, 3119.	1.6	0
102	Melanoma metastasis is associated with enhanced expression of the syntenin gene. Oncology Reports, 2004, 12, 221-8.	1.2	24
103	TACE is required for the activation of the EGFR by TGF-Î± in tumors. EMBO Journal, 2003, 22, 1114-1124.	3.5	261
104	Protein Ectodomain Shedding. ChemInform, 2003, 34, no.	0.1	0
105	Impaired Trafficking and Activation of Tumor Necrosis Factor-Î±-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding. Journal of Biological Chemistry, 2003, 278, 25933-25939.	1.6	44
106	Shedding of plasma membrane proteins. Current Topics in Developmental Biology, 2003, 54, 125-144.	1.0	27
107	ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clinical Cancer Research, 2003, 9, 1274-83.	3.2	181
108	Protein Ectodomain Shedding. Chemical Reviews, 2002, 102, 4627-4638.	23.0	223

#	Article	IF	Citations
109	The proteasome is a major autoantigen in multiple sclerosis. Brain, 2002, 125, 2658-2667.	3.7	48
110	Metalloprotease-dependent Protransforming Growth Factor-Î± Ectodomain Shedding in the Absence of Tumor Necrosis Factor-Î±-converting Enzyme. Journal of Biological Chemistry, 2001, 276, 48510-48517.	1.6	119
111	Mechanism of action of trastuzumab and scientific update. Seminars in Oncology, 2001, 28, 4-11.	0.8	207
112	Mechanism of action of trastuzumab and scientific update. Seminars in Oncology, 2001, 28, 4-11.	0.8	234
113	Proteolytic Processing and Assembly of the C5 Subunit into the Proteasome Complex. Journal of Biological Chemistry, 2000, 275, 6592-6599.	1.6	12
114	The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein. Molecular Biology of the Cell, 2000, 11, 4217-4225.	0.9	26
115	Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity. Journal of Biological Chemistry, 1999, 274, 3531-3540.	1.6	284
116	A Role for a PDZ Protein in the Early Secretory Pathway for the Targeting of proTGF-Î± to the Cell Surface. Molecular Cell, 1999, 3, 423-433.	4.5	140
117	Mechanisms controlling the shedding of transmembrane molecules. Biochemical Society Transactions, 1999, 27, 243-246.	1.6	18
118	Pro-Tumor Necrosis Factor-Î± Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing. Journal of Biological Chemistry, 1998, 273, 24955-24962.	1.6	77
119	Role of the Juxtamembrane Domains of the Transforming Growth Factor-Î± Precursor and the Î²-Amyloid Precursor Protein in Regulated Ectodomain Shedding. Journal of Biological Chemistry, 1997, 272, 17160-17165.	1.6	104
120	Phosphorylation of C8 and C9 Subunits of the Multicatalytic Proteinase by Casein Kinase II and Identification of the C8 Phosphorylation Sites by Direct Mutagenesis. Biochemistry, 1996, 35, 3782-3789.	1.2	102
121	Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors. Journal of Biological Chemistry, 1996, 271, 11376-11382.	1.6	371
122	Transforming growth factor-alpha and beta-amyloid precursor protein share a secretory mechanism.. Journal of Cell Biology, 1995, 128, 433-441.	2.3	151
123	Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochemical Journal, 1993, 296, 93-97.	1.7	50
124	Modulation of the Multicatalytic Proteinase Complex by Lipids, Interconversion and Proteolytic Processing. Enzyme & Protein, 1993, 47, 285-295.	1.6	16
125	Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus.. Journal of Experimental Medicine, 1991, 173, 423-427.	4.2	33
126	Melanoma metastasis is associated with enhanced expression of the syntenin gene. Oncology Reports, 0, , .	1.2	20